Advertisement
Nontraditional markers help doctors pinpoint who needs aggressive treatment
Many of us know that cholesterol, blood sugar, blood pressure, body-mass index and smoking are modifiable risk factors for heart disease. If you smoke or have high levels of the other risk factors, you will need to make lifestyle changes and/or take medications to prevent a heart attack. But these measures don’t always stop a serious cardiac event from occurring.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Treating these risk factors reduces heart attacks by 50 percent. This means 50 percent still happen,” says Stanley Hazen, MD, PhD, Co-section Head of Preventive Cardiology and Rehabilitation.
Researchers have looked long and hard for additional ways to improve risk prediction. Over the years, many substances in the blood have been identified as possibilities. However, only a small number of these biomarkers have been proven effective enough to be widely adopted.
We want to be able to identify people who remain at risk, so we can treat them more aggressively to attenuate that risk.
At Cleveland Clinic, nontraditional biomarkers in routine use include high-sensitivity C-reactive protein (hsCRP), lipoprotein(a), homocysteine, trimethylamine N-oxide (TMAO), myeloperoxidase and N-terminal pro-brain natriuretic peptide (NT-proBNP).
“All have significant data supporting findings that they provide independent prognostic value beyond traditional risk factors,” says Dr. Hazen.
Here we explain what these biomarkers are, and why your doctor might want to test for one of them:
hsCRP. HsCRP indicates inflammation is present somewhere in the body. High CRP levels are associated with higher risk of coronary artery disease (CAD) and heart attack.
In clinical trials, hsCRP was shown to be a reliable indicator of patients who would substantially benefit from more intensive statin therapy.
Advertisement
“The test is useful for identifying people whose elevated risk was not picked up by tests for traditional risk factors, as well as those who remain at risk, despite being on treatment. I order a CRP test at the first visit to see if a patient’s statin therapy is adequate or needs to be more aggressive,” Dr. Hazen explains.
Myeloperoxidase. Myeloperoxidase is a marker of inflammation in the blood vessels. A high level signifies an increased risk of heart attack.
“We may measure myeloperoxidase at a patient’s initial visit in order to determine our LDL goal. If myeloperoxidase levels are high, we will be more aggressive with antiplatelet and LDL-lowering therapy,” he says.
Lipoprotein(a). Lipoprotein(a) is a genetic marker of increased risk of CAD and heart attack in men under age 55 and all women, especially those over age 55.
In patients with a strong family history of CAD, high lipoprotein(a) levels indicate higher risk. “We recommend all first-degree relatives of these patients be screened,” says Dr. Hazen.
Because lipoprotein(a) is attached to LDL cholesterol, more aggressive lowering of LDL is necessary to lower risk. Aspirin also may be prescribed to decrease an elevated risk of thrombosis (blood clots).
Homocysteine. Every 10 percent rise in homocysteine levels is associated with a 10 percent increased risk of CAD. However, lowering homocysteine does not decrease risk.
Currently, homocysteine is used primarily to identify which patients with chronic kidney disease (CKD) are at increased risk for a cardiac event. “We are more aggressive with blood pressure and cholesterol reduction in these patients,” says
Dr. Hazen.
TMAO. TMAO makes blood platelets prone to clotting. High levels of TMAO have been found to be a strong predictor of increased risk for a heart attack or stroke caused by a blood clot.
Dr. Hazen led Cleveland Clinic’s team that discovered this biomarker. They subsequently, developed a blood test that is now available nationwide to determine TMAO levels. More recently, they developed a new type of drug that
blocks the formation of TMAO in the gut.
NT-proBNP. BNP is a hormone that causes blood pressure to rise and the body to retain sodium and water. High levels of NT-proBNP can alert doctors to worsening left ventricular ejection fraction, making the test valuable for diagnosing heart failure in asymptomatic patients.
“When we see NT-proBNP levels are high, we take extra care to make sure blood pressure is well controlled with standard heart failure medications,” says Dr. Hazen.
Advertisement
This article originally appeared in Cleveland Clinic Heart Advisor.
Advertisement
Learn more about our editorial process.
Advertisement
Although allulose is an FDA-approved sugar substitute, more research is needed to understand its safety
Studies show those who walk faster tend to have a lower risk of heart disease
Recognizing subtle symptoms, like cold sweats, stomach discomfort and nausea, could be the key to survival
Statin use has been associated with weight gain but the reasons aren’t clear — and the benefits of statins far outweigh the risks
Some statins have been shown to slightly increase your risk of diabetes — but that shouldn’t keep you from taking the medication you need
Research points to an association between the health of your gums and cardiovascular disease
Factors like temperature, energy levels and sleep quality play a role in determining whether working out in the morning or evening is best for you
Lifestyle adjustments can help you raise your HDL, the ‘good’ cholesterol
Focus on your body’s metabolic set point by eating healthy foods, making exercise a part of your routine and reducing stress
PFAS chemicals may make life easier — but they aren’t always so easy on the human body
While there’s little risk in trying this hair care treatment, there isn’t much science to back up the claims